Hazlett Burt & Watson Inc. Has $2.27 Million Stake in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Jul 24th, 2023

Hazlett Burt & Watson Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,664 shares of the company’s stock after purchasing an additional 153 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Hazlett Burt & Watson Inc.’s portfolio, making the stock its 10th largest position. Hazlett Burt & Watson Inc.’s holdings in Johnson & Johnson were worth $2,273,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GW&K Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $35,000. Dark Forest Capital Management LP boosted its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares during the last quarter. Retirement Financial Solutions LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $40,000. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $42,000. Finally, Kepos Capital LP purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $45,000. Institutional investors own 67.57% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

JNJ stock opened at $170.19 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $160.37 and its 200 day moving average is $161.25. The stock has a market cap of $442.28 billion, a price-to-earnings ratio of 34.45, a price-to-earnings-growth ratio of 2.88 and a beta of 0.55. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.59 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on JNJ shares. UBS Group started coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. Atlantic Securities cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday. Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a report on Friday. Finally, Raymond James dropped their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $171.40.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.